About this Event
The Innovation @ Penn program is honored to welcome Katalin Kariko, PhD, who co-discovered (with Penn Medicine colleague Drew Weissman) that nucleoside modifications suppress the immunogenicity of RNA, which has widened the therapeutic potential of mRNA in treating diseases. This led to the development of the two most effective vaccines for COVID-19, the BioNTech/Pfizer and Moderna vaccines, and holds vast promise for future treatments of many other diseases.
Joining Dr. Kariko for a discussion about the future of mRNA Technology will be one of Penn’s leading faculty innovators working on mRNA manufacturing technology Michael J. Mitchell, PhD, the J. Peter and Geri Skirkanich Professor of Innovation at Penn Engineering. The program will be moderated by Beth Seidenberg MD, Founding Managing Director of Westlake Village Partners.
Networking reception to follow.
Event Venue & Nearby Stays
Wharton San Francisco, 2 Harrison Street, San Francisco, United States
USD 0.00